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The tachykinin neurokinin B (NKB, Tac2) is critical for proper GnRH release in mammals, 
however, the role of the other tachykinins, such as substance P (SP) and neurokinin A (NKA) in 
reproduction, is still not well understood.  In this study, we demonstrate that NKA controls the 
timing of puberty onset (similar to NKB and substance P) and stimulates LH release in adulthood 
through NKB-independent (but kisspeptin-dependent) mechanisms in the presence of sex 
steroids. Furthermore, this is achieved, at least in part, through the auto-synaptic activation of 
Tac1 neurons, which express NK2R (Tacr2), the receptor for NKA. Conversely, in the absence of 
sex steroids, as observed in ovariectomy, NKA inhibits LH through a mechanism that requires the 
presence of functional receptors for NKB and dynorphin (NK3R and KOR, respectively). 
Moreover, the ability of NKA to modulate LH secretion is absent in Kiss1KO mice, suggesting that 
its action occurs up-stream of Kiss1 neurons.  Overall, we demonstrate that NKA signaling is a 
critical component in the central control of reproduction, by contributing to the indirect regulation 





















Tachykinins (TACs) are a large family of peptides that include neurokinin A  and substance P 3 
(NKA and SP; encoded by TAC1), and neurokinin B (NKB;encoded by TAC3 or Tac2 in rodents) 4 
(1). TACs act preferentially on different G protein-coupled receptors: NK1R (encoded by Tacr1, 5 
the receptor for SP), NK2R (encoded by Tacr2, the receptor for NKA) and NK3R (encoded by 6 
Tacr3, the receptor for NKB). These TAC systems are expressed throughout the central nervous 7 
system, where they participate in a variety of physiological functions, e.g. nociception and fear 8 
conditioning (1,2).  9 
The NKB/NK3R signaling system has emerged as a critical neuroendocrine regulator of 10 
reproductive function. A growing body of evidence from our lab and others has documented the 11 
stimulatory role of NKB on GnRH release, in an estradiol and kisspeptin dependent manner, in all 12 
studied species including humans (3). In addition to NKB, the SP/NK1R signaling system also 13 
participates in the central regulation of the gonadotropic axis, as supported by the following 14 
studies: (a) the central administration of SP induces LH release in rabbits and rats (4-6), (b) 15 
electrophysiology studies showed activation of Kiss1 neurons by SP (7), (c) SP mRNA and protein 16 
have been found in the ARC of rodents (8,9) and (d) SP immunoreactivity has been detected 17 
within Kiss1 and NKB neurons in the human infundibular nucleus (10). Interestingly, we have 18 
recently shown that  chronic SP administration advances puberty onset in rodents (11) and that 19 
Tac1KO mice with congenital absence of SP display delayed puberty onset and reproductive 20 
impairments (11,12). However, Tac1 encodes both SP and NKA and thus, the reproductive 21 
defects we observe in Tac1KO mice may be, at least in part, due to the absence of NKA signaling. 22 
Importantly, we and others have documented that NKA induces LH release in mice and rats 23 
(9,13,14) in a kisspeptin-dependent manner (9). Furthermore, the stimulatory action of NKA on 24 
LH release is dependent on the presence of physiological levels of circulating sex steroids (9) and 25 
in their  absence, such as during ovariectomy (OVX), NKA inhibits LH release, similar to NKB (9). 26 
However, unlike NKB, the receptor for NKA (NK2R) is not present on Kiss1 or GnRH neurons (9). 27 
Therefore, we hypothesize that NKA must act upstream of Kiss1 upon an unknown population of 28 
neurons, that in turn control NKB release. Alternatively, all TAC ligand-receptor systems have 29 
been reported to display cross-reactivity (15), suggesting that cross-activation of NK3R could 30 
account for the NKB-like action of NKA. 31 
Overall, there is compelling evidence that all TACs (not only NKB) participate in the control of 32 
GnRH release. Thus, deciphering TAC’s individual and/or potential synergistic mechanism of 33 
action, could provide important insight into the neuroendocrine control of reproduction.  34 
Interestingly, a number of human patients with TAC3/TACR3 mutations have been reported to 35 
overcome initial pubertal failure and central hypogonadotropic hypogonadism (HH) (16). These 36 
patients present an ‘awakening’ of GnRH secretion and hypogonadism reversal (16), a phenotype 37 
that resembles that of Tacr3KO mice, which are subfertile (17). This further suggests that in the 38 
absence of NKB signaling, compensation by NKA (and/or SP) may restore GnRH/LH secretion.  39 
Thus, in this study, we aim to characterize the role of NKA in the control of GnRH release during 40 
puberty onset and adulthood in a series of pharmacological and genetic experiments in WT, 41 
Tac2KO and Kiss1KO female mice, with special interest in the interactions between the 42 
NKA/NK2R and NKB/NK3R systems. 43 
 44 
Materials and Methods 45 
Mice. Wild-type (WT) female C57Bl/6 mice were purchased from Charles River Laboratories 46 
International, Inc. Tac2 KO (knockout, KO) mice were obtained from Dr. Seminara (MGH, Boston, 47 
MA) (18). Kiss1KO were obtained from Dr. Richard Palmiter (University of Washington, Seattle, 48 
WA) (19). Tac2KO and Kiss1KO mice were compared to their WT littermates. All animal studies 49 
were approved by the Harvard Medical Area Standing Committee on the Use of Animals in 50 
Research and Teaching in the Harvard Medical School Center for Animal Resources and 51 
Comparative Medicine. Mice were maintained in a 12:12 h light/dark cycle and were fed standard 52 
rodent chow diet and water ad libitum. Genotyping was conducted by PCR analyses on isolated 53 
genomic DNA from tail biopsies.  54 
 55 
Reagents: The agonists for NK1R (GR73632), NK2R (GR64349) and NK3R (senktide), and the 56 
antagonists for NK3R (SB 222200) and NK1R (RP67580) were purchased from Tocris. Naloxone 57 
Hydrochloride (opioid receptor antagonist) and GnRH were purchased from Sigma Aldrich. Mouse 58 
kisspeptin-10 (Kp-10) was purchased from Phoenix pharmaceutical. All drugs were dissolved in 59 
saline (0.9% NaCl), except for SB 222200 and RP67580, which were dissolved in 5% DMSO. 60 
Doses and timing for hormonal analyses were selected on the basis of previous studies (9,20,21). 61 
 62 
Experimental design 63 
General procedures: For intracerebroventricular (icv) injections, the mice were briefly 64 
anesthetized with isoflurance 2-3 days before the experiment and a small hole was bored in the 65 
skull (1 mm lateral and 0.5 mm posterior to bregma) using  a Hamilton syringe (27-gauge needle 66 
fitted with polyethylene tubing, leaving 3.5 mm of the needle tip exposed). All subsequent 67 
injections were made through this site. For icv injections, mice were anesthetized with isoflurane 68 
for a total of 2–3 min, during which time 5 μl of solution were slowly and continuously injected into 69 
the lateral ventricle. The needle remained inserted for approximately 60 sec after the injection to 70 
minimize backflow up the needle track. Mice typically recovered from the anesthesia within 3 min 71 
after the injection. For hormonal analyses, blood samples (4 µl) were obtained from the tail at 0, 72 
26 and 60 min after an icv injection, and stored at −80°C until further processing. The dose and 73 
time of blood sampling were selected based on our previous studies (9). 74 
 75 
Study 1: Effect of chronic NK2R-Ag administration in pre-pubertal mice.  76 
To investigate whether NKA/NK2R signaling plays a role in puberty onset, we performed a 77 
systemic chronic (from 23d to 32d) administration of NK2R-Ag (3 nmol/100μl/i.p./every 12h) or 78 
vehicle (0.9% NaCl) to WT female mice (n≥6 per group). Reproductive maturation (i.e., 79 
progression of vaginal opening; VO) was monitored daily. Body weight (BW) was recorded at day 80 
30 when 50% of control females showed VO. Lastly, uterine and ovarian weights, as well as LH 81 
concentrations, were determined at day 32, the final day of NK2R-Ag administration.  82 
Study 2: Interaction between NKA, NKB and SP for the stimulation of LH release in the presence 83 
of estradiol.  84 
In this study, adult WT female mice were subjected to bilateral OVX under light isofluorane 85 
anesthesia, 1 week before pharmacological tests. Immediately after OVX, capsules filled with 86 
diluted crystalline of 17β-estradiol (E2) or vehicle (sesame seed oil) were implanted 87 
subcutaneously (sc) via a small midscapular incision at the base of the neck (OVX+E2). Silastic 88 
tubing (15 mm long, 0.078 in inner diameter, 0.125 in outer diameter; Dow Corning) was used for 89 
capsule preparation. A low dose  of crystalline E2 (50 μg/mL, in sesame oil) was used to fill the 90 
capsules which were sealed with silicone cement and allowed to cure overnight. The day before 91 
surgery, implants were washed twice for 10 min in changes of 100% ethanol and then placed in 92 
sterile physiological saline overnight.  93 
First, we aimed to investigate the potential additive effect of the NK2R-Ag and senktide on LH 94 
secretion in the presence of sex steroids. To this end, LH levels were measured in WT OVX+E2 95 
females (n≥5 per group), 25 and 60 min after an icv injection of NK2R-Ag (600pmol), senktide 96 
(600pmol) or the co-administration of both drugs. Next, WT OVX+E2 females (n≥5 per group) 97 
were pretreated with the NK3R antagonist SB222200 (7 nmol), 60 minutes prior to the icv injection 98 
of NK2R-Ag (600 pmol, senktinde or vehicle (0.9% NaCl). Blood samples were collected before 99 
SB222200 injection (basal) and at 25 and 60 minutes after injection of the agonists. Additionally, 100 
we further investigated the action of NK2R-Ag in the absence of NKB signaling using Tac2KO  101 
OVX+E2 females and their corresponding WT littermate controls (WT OVX+E2; n≥5 per group). 102 
Both groups of females were injected with NK2R-Ag (600 pmol) and blood samples were collected 103 
before and 25 and 60 min after injection. Finally, in order to evaluate whether the action of NKA 104 
requires kisspeptin to stimulate LH release, we used Kiss1KO OVX+E2 females and their 105 
corresponding WT littermate controls (WT OVX+E2; n≥5 per group) and LH levels were measured 106 
25 min after icv injection of NK2R-Ag (600 pmol). 107 
 108 
Study 3: Interaction between NKA, NKB and SP for the inhibition of LH release in 109 
ovariectomizedfemale mice. 110 
 Adult WT females were subjected to bilateral OVX under light isoflurane anesthesia 1 week 111 
before pharmacological tests. First, we aimed to investigate the potential additive effect of NK2R-112 
Ag and senktide in the inhibition of LH secretion in the absence of sex steroids.  Thus, LH levels 113 
were measured in WT OVX females (n≥5 per group), 25 and 60 min after an icv injection of NK2R-114 
Ag (600pmol), senktide (600pmol) or the co-administration of both drugs.  In the next experiment, 115 
we intended to assess the role of NKB in the inhibition of LH secretion achieved by NKA, in WT 116 
OVX females. To this end, LH responses to the NK2R-Ag were evaluated after blockade of the 117 
effects of NKB using SB222200 (7 nmol) as a selective antagonist for NK3R. For this purpose, 118 
adult WT OVX  female mice (n≥5 per group) were pretreated with SB222200 60 minutes prior to 119 
the icv injection of NK2R-Ag (600 pmol). Blood samples were collected before SB222200 injection 120 
(basal) and at 25 and 60 minutes after vehicle or NK2R-Ag injection. In addition, we investigated 121 
the role of endogenous opioids in the control of LH secretion and in the modulation of LH 122 
responses to NK2R, using adult WT OVX females.To this end, LH responses to NK2R-Ag were 123 
measured after the blockade of the  and  opioid receptors (KOR and MOR) using naloxone 124 
(5mg/kg/100ul/ip). All animals (WT OVX females; n≥5 per group) were injected with naloxone, 12 125 
hours and then 60 minutes prior to the icv injection of NK2R-Ag (600 pmol). Blood samples were 126 
collected before naloxone injection and at 25 and 60 minutes after NK2R-Ag injection. We further 127 
investigated the action of NK2R-Ag in the absence of NKB signaling and sex steroids using 128 
Tac2KO OVX and WT OVX females (n≥5 per group). Both groups of animals were injected with 129 
NK2R-Ag (600 pmol) and blood samples were collected before and then 25 and 60 min after 130 
injection. In addition, we evaluated the role of SP in the NK2R-Ag induced inhibition of LH in WT 131 
OVX and Tac2KO OVX mice (n≥5 per group). Both groups of females were injected with NK1R-132 
Antg (2 nmol), 30 min before the administration of NK2R-Ag (600 pmol), NK1R-Ag (600 pmol) or 133 
vehicle. Blood samples were collected before and then 25 and 60 min after injection. Finally, we 134 
assessed the ability of NK2R signaling to modulate LH release in the absence of kisspeptin and 135 
sex steroids using Kiss1KO OVX and WT OVX females (n≥5 per group), which were injected with 136 
NK2R-Ag (600 pmol) and LH levels were measured at 25 and 60 min after icv injection. 137 
 138 
Study 4: Expression of Tacr1, Tacr2, Tacr3, Kiss1 and Pdyn in the mediobasal hypothalamus 139 
(MBH) of female mice.  140 
We aimed to determine if there are changes in the expression of Tacr1, Tacr2, Tacr3, Kiss1, and 141 
Pdyn in the mediobasal hypothalamus (MBH), the site that includes the arcuate nucleus (ARC) 142 
between WT (n = 7) and Tac2 KO (n = 9) ovary-intact females. 143 
Total RNA from the MBH was isolated using TRIzol reagent (Invitrogen) followed by 144 
chloroform/isopropanol extraction. RNA was quantified using NanoDrop 2000 spectrophotometer 145 
(Thermo Scientific), and 1 μm of RNA was reverse transcribed using iScript cDNA synthesis kit 146 
(Bio-Rad). Quantitative real-time PCR assays were performed on an ABI Prism 7000 sequence 147 
detection system, and analyzed using ABI Prism 7000 SDS software (Applied Biosystems). The 148 
cycling conditions were the following: 2 min incubation at 95°C (hot start), 45 amplification cycles 149 
(95°C for 30 s, 60°C for 30 s, and 45 s at 75°C, with fluorescence detection at the end of each 150 
cycle), followed by melting curve of the amplified products obtained by ramped increase of the 151 
temperature from 55 to 95°C to confirm the presence of single amplification product per reaction. 152 
For data analysis, relative standard curves were constructed from serial dilutions of one reference 153 
sample cDNA and the input value of the target gene was standardized to Hprt levels in each 154 
sample. The primers used are listed in Table 1. 155 
 156 
In situ hybridization (ISH): To determine the presence of co-expression between Tac2r and 157 
Tac1 mRNA in key areas (ventromedial nucleus, VMN; and ARC), dual fluorescence ISH was 158 
performed in tissue samples from OVX+sham and OVX+E2 mice. We used probes for Tac2r-C1 159 
and Tac1-C2 obtained from ACDBio and used the RNAscope method per their protocol (ACDBio). 160 
The brains were removed for ISH, fresh frozen on dry ice, and then stored at −80°C until 161 
sectioning. Five sets of 20-μm sections in the coronal plane were cut on a cryostat, from the 162 
diagonal band of Broca to the mammillary bodies, thaw mounted onto SuperFrost Plus slides 163 
(VWR Scientific), and stored at −80°C. A single set was used for ISH experiment (adjacent 164 
sections 100 μm apart). 165 
 166 
Hormone measurements: LH was measured by a sensitive sandwich ELISA for the assessment 167 
of whole blood LH concentrations (22). A 96-well high-affinity binding microplate (9018; Corning) 168 
was coated with 50uL of capture antibody (monoclonal antibody, anti-bovine LH beta subunit, 169 
518B7; University of California) at a final dilution of 1:1000 (in 1XPBS, 1.09 g of Na2HPO4 [an-170 
hydrous], 0.32 g of NaH2PO4 [anhydrous], and 9g of NaCl in1000 mL of distilled water) and 171 
incubated overnight at 4°C. To minimize unspecific binding of the capture antibody, wells were 172 
incubated with 200uL of blocking buffer (5% [w/v] skim milk powder in 1XPBS-T (1XPBS with 173 
0.05% Tween20) for 2hours at room temperature (RT). A standard curve was generated using a 174 
2-fold serial dilution of LH (reference preparation, AFP-5306A; National Institute of Diabetes and 175 
Digestive and Kidney Diseases National Hormone and Pituitary Program [NIDDK-NHPP]) in 0.2% 176 
(w/v) BSA-1XPBS-T. The LH standards and blood samples were incubated with 50 uL of detection 177 
antibody (polyclonal antibody, rabbit LH antiserum, AFP240580Rb; NIDDK-NHPP) at a final 178 
dilution of 1:10000 for 1.5 hours (at RT). Each well containing bound substrate was incubated 179 
with 50 ul of horseradish peroxidase conjugated antibody (polyclonal goat anti-rabbit, D048701–180 
2; DakoCytomation) at a final dilution of 1:2000. After a 1.5-hour incubation, 100Ul of o-181 
phenylenediamine (002003;Invitrogen), substrate containing 0.1% H2O2 was added to each well 182 
and left at RT for 30minutes.The reaction was stopped by addition of 50 uL of 3M HCl to each 183 
well, and absorbance of each well was read at a wave length of 490 nm (Sunrise; Tecan Group). 184 
The concentration of LH in whole blood samples was determined by interpolating the OD values 185 
of unknowns against a nonlinear regression of the LH standard curve (22). 186 
 187 
Statistical Analysis: All data are expressed as the mean ± SEM for each group. A two tailed 188 
unpaired t-Student test or a one- or two-way ANOVA test followed by Tukey or Newman Kleus 189 
post-hoc test was used to assess variation among experimental groups. Significance level was 190 
set at P < 0.05. All analyses were performed with GraphPad Prism Software, Inc (San Diego, CA). 191 
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1. Advancement of puberty onset after chronic activation of NK2R in female mice. 201 
Our previous studies have demonstrated that chronic administration of specific agonists for the 202 
NK1R and NK3R receptor are able to advance puberty onset in mice and rats (11,20), indicating 203 
that these systems are in place before puberty and likely participate in the proper timing of puberty 204 
onset. However, whether NKA/NK2R signaling is also involved in the awakening of the 205 
gonadotropic axis at the time of puberty is unknown. To address this question, we chronically 206 
(every 12h) treated WT females with a specific agonist of NK2R from weaning age (22d) to 32d. 207 
We observed that this treatment was able to advance puberty onset as evidenced by the 208 
advanced timing of VO and increased uterine and ovarian weight compared to controls [uterine 209 
weight: 19.55  1.89 mg versus 23.79  1.61 mg in control and NK2R-Ag treated females, 210 
respectively (*p < 0.05) and ovarian weight: 8.3 ± 0.56 mg versus 11.7 ± 0.44 mg in control and 211 
NK2R-Ag treated females, respectively (***p < 0.001); Figure 1 A-F].  BW at 30d was not different 212 
between groups.  213 
 214 
2. The receptor for NKA (NK2R) is expressed in VMH Tac1 neurons. 215 
We have previously documented the existence of mRNA for the NKB receptor (NK3R) and SP 216 
receptor (NK1R) in Kiss1 neurons in the ARC, while the receptor for NKA (NK2R) was 217 
undetectable in Kiss1 or GnRH neurons (9). We therefore aimed to assess if NK2R (encoded by 218 
Tacr2) is expressed in other neurons located in the ARC or ventromedial hypothalamus (VMH) 219 
and whether it colocalizes with Tac1 neurons in these areas as the source of SP and NKA. Our 220 
in situ hybridization (RNAscope) results showed that Tacr2 is expressed in both ARC and VMH 221 
nuclei and colocalizes with virtually all Tac1 neurons in the VMH of adult WT mice regardless of 222 
the E2 milieu (Figure 2). 223 
 224 
3. The stimulatory action of NKA is independent of NKB but dependent of kisspeptin. 225 
We previously reported that the action of NKA and NKB on LH release is largely equivalent, i.e. 226 
both increase LH release in the presence of physiological circulating levels of E2, but inhibit LH in 227 
the absence of sex steroids (9). It was, therefore, tentative to speculate that NKA could induce 228 
LH release through the stimulation of NKB given the absence of NK2R in Kiss1 and GnRH 229 
neurons. To test this hypothesis, first we co-administered NK2R and NK3R agonists inOVX + E2 230 
WT mice and observed that the increase in LH was similar in groups injected with an individual 231 
dose of each agonist or the combination of both (Figure 3 A), eliminating the possibility of an 232 
additive effect of NKA and NKB on LH release and suggesting a possible common pathway. Next, 233 
to evaluate if NKA requires NKB signaling to induce LH release, the LH response to NK2R-Ag 234 
was tested in the presence of an NK3R antagonist (Figure 3 A) or in NKB deficient (Tac2KO) 235 
mice (Figure 3 B). In both cases, NK2R-Ag was able to significantly stimulate LH release 236 
indicating that NK2R activation induces LH release independently of the presence of NKB or its 237 
receptor NK3R. However, NK2R signaling requires the presence of kisspeptin as Kiss1KO mice 238 
replaced with E2 did not have any effect on LH release (WT Basal: 0.27  0.06 ng/mL, WT NK2R-239 
Ag: 0.57  0.09 ng/mL; *p < 0.05;   Kiss1KO Basal: 0.21  0.02 ng/mL, Kiss1KO NK2R-Ag: 0.29 240 
 0.04 ng/mL; not significant). 241 
 242 
4. The inhibitory action of NKA is NKB and dynorphin dependent. 243 
In the next set of experiments, we sought to determine whether the inhibitory action of NKA/NK2R 244 
on LH release in the absence of sex steroids (i.e. OVX) is mediated by NKB or dynorphin. First, 245 
we showed that the inhibitory action of NK2R-Ag + senktide was similar to that of senktide alone, 246 
suggesting (as in the presence of E2) that there is no additive effect of both tachykinins in the 247 
inhibition of LH (Figure 4 A). The use of the specific NK3R antagonist alone decreased LH in 248 
OVX animals, in line with recent literature showing that blockade of NK3R decreases LH pulsatility 249 
(23-26). However, co-administration of the NK3R antagonist and the NK2R-Ag failed to induce a 250 
further decrease in LH, suggesting that NK3R signaling is required for the inhibitory action of NKA 251 
in the absence of E2 (Figure 4 A). Moreover, as previously described in rats, NK2R signaling 252 
requires dynorphin to inhibit LH (27), which is prevented after the blockade of the KOR and MOR 253 
using naloxone (Figure 4 B). Of note, naloxone alone also inhibited LH release in OVX mice, in 254 
line with our previous reports in OVX PdynKO and Oprk1KO mice (dynorphin KO and KOR KO 255 
mice, respectively) (28), suggesting that the absence of the inhibitory signal of dynorphin leads to 256 
a significant decrease in the ability of the mouse to secrete LH, probably due to disruption of the 257 
LH pulse generator mechanism (29). Next, we assessed the action of NK2R-Ag in the congenital 258 
absence of NKB (OVX Tac2KO mice) to further confirm the data obtained after NK3R blockade. 259 
Unexpectedly, we observed that the absence of NKB leads to a robust induction of LH release 260 
(Figure 5 A), revealing an action that is not present in WT OVX regardless of whether a functional 261 
NK3R is present or antagonized.  262 
Because we have observed that VMH Tac1 neurons co-express Tacr2 (NK2R) (Figure 263 
2), we hypothesized that NKA could be inducing LH release in Tac2KO mice through the 264 
stimulation of SP from Tac1 neurons that, in turn, would activate Kiss1 neurons (9). To test this 265 
hypothesis, we administered the NK2R-Ag in the presence of a NK1R antagonist (Figure 5 A) 266 
[proven to efficiently block the action of a NK1R- agonist (Figure 5 B)] in Tac2KO OVX mice. 267 
NK2R-Ag was still able to induce LH release after NK1R blockade although the magnitude of this 268 
increase tended to be lower than in the absence of the NK1R antagonist (Figure 5 A). Lastly, we 269 
confirmed that this action is kisspeptin-dependent by showing complete absence of LH response 270 
after the administration of NK2R-Ag in Kiss1 KO mice (WT: Basal 2,90  0.42 ng/mL, NK1R-Ag 271 
2.08  0.32 ng/mL, *p < 0.05; Kiss1KO: Basal 0.32  0.06 ng/mL, NK1R-Ag 0.30  0.02 ng/mL, 272 
not significant). In order to assess whether this striking difference between the response to NK2R 273 
agonists after the pharmacological blockade of NK3R and the congenital absence of the NK3R 274 
ligand (NKB) is due to compensation in the expression of any of the ligand-receptor components 275 
of the tachykinin systems or in dynorphin, we evaluated the expression of these genes in the MBH 276 
of WT vs. Tac2KO female mice. We observed a significant increase in the expression of Tacr3 277 
(NK3R) in Tac2KO mice compared to controls (Figure 5 C). 278 
 279 
Discussion 280 
The neuroendocrine mechanisms controlling the timing of puberty onset remain largely 281 
unknown. Among the stimulatory signals that increase their synthesis and release in the late 282 
juvenile period to induce the awakening of the reproductive axis, kisspeptin plays a pivotal role 283 
(30). Inactivating mutations in the KISS1/KISS1R genes lead to HH and absent puberty onset 284 
(31,32), while gain of function mutations in KISS1R advances puberty onset in humans (33). 285 
Similarly, chronic administration of kisspeptin-10 advances puberty onset in rodents (34). 286 
However, the pattern of kisspeptin release is dependent on upstream regulators, such as the 287 
tachykinin peptides (ref). For example, the tachykinin NKB, acts autosynaptically in ARC Kiss1 288 
neurons, and its activation precedes that of kisspeptin, to allow for the proper timing of puberty 289 
onset (28,35-38). Moreover, we have recently documented that the tachykinin SP, originating 290 
from Tac1 neurons and located upstream of Kiss1, is also involved in puberty initiation (11,12). In 291 
this study, we expand these findings to include NKA, and demonstrate that prepubertal female 292 
mice exhibit a premature activation of the reproductive axis in response to this tachykinin. , chronic 293 
activation of the NKA receptor (NK2R) during this developmental period, advances puberty onset 294 
in female mice, as observed by the advanced age of vaginal opening and increased ovarian and 295 
uterine weights.. While this finding demostrates that the animal is able to respond to the 296 
stimulatory action of NKA prepuberally, further studies will be required to determine the 297 
contribution of NKA on the timing of puberty onset. However, this finding suggests that the delay 298 
in puberty onset observed in Tac1KO mice (11) may be due to the loss of the stimulatory action 299 
of both SP and NKA on kisspeptin release.  300 
Interestingly, while the vast majority of ARC Kiss1 neurons express NK3R (Tacr3) and 301 
approximately half express NK1R (Tacr1), no detectable expression of NK2R (Tacr2) has been 302 
found in Kiss1 neurons or GnRH neurons (9). This suggests that the primary action of NKA must 303 
lie upstream of Kiss1 neurons. In this study, we identified Tacr2 in the majority (x%) of Tac1 304 
neurons located in the VMH. Whether this population of Tac1 neurons is the main source of NKA 305 
that elicits gonadotropin release is still unclear and will require the use of genetic mouse and viral 306 
models. Nonetheless, the high degree of colocalization between  the ligand (NKA encoded by 307 
Tac1) and it’s receptor (Tacr2), as observed in the VMH, is reminiscent of the NKB/NK3R 308 
signaling mechanism in ARC Kiss1 neurons and suggests the existence of an autosynaptic loop 309 
that may modulatethe release of SP onto Kiss1 neurons. Of note, a scarce population of Tac1 310 
neurons is also present in the ARC, and adjacent to Kiss1 neurons (9). However, these neurons 311 
do not express Tacr2 and their role, if any, in the control of Kiss1 neurons remains to be 312 
characterized. 313 
 314 
In this study we also addressed the question of whether the analogous action of NKA and NKB 315 
in the regulation of LH release (i.e. stimulation in the presence of E2 and inhibition in its absence 316 
(9)) is due to the convergence of the NKA mechanism of action onto NKB signaling. Despite the 317 
aforementioned functional similarities, our data using an NK3R antagonist and Tac2KO mice after 318 
OVX or OVX and E2 replacement, clearly demonstrate that the stimulatory action of NKA on LH 319 
is NKB independent but kisspeptin-dependent, suggesting the existence of a yet unknown 320 
population of NKA-responsive neurons that in turn activate Kiss1 neurons to induce 321 
kisspeptin/GnRH release (Figure 6). In contrast, NKA has been shown to inhibit LH via a 322 
mechanism which involves dynorphin in the rat (14,27) similar to what has been described for 323 
NKB in the absence of E2 (39). Here, we show that the inhibitory action of NKA is weaker than the 324 
one exerted by NKB as observed 60 min after treatment, when NK2R agonist’s action on the 325 
inhibition of LH release is lost, while this inhibition reaches a maximal level for the NK3R agonist. 326 
Furthermore, we demonstrate that the inhibitory action of NKA is mediated by the activation of 327 
the NKB–dynorphin signaling pathway since blockade of both NK3R and KOR receptors 328 
prevented the inhibition of LH induced by the NK2R agonist. Importantly, the action of stimulating 329 
or inhibiting NK3R and KOR in both cases leads to the inhibition of LH release in the absence of 330 
sex steroids that is of equal magnitude 25 min after the treatment, likely as a consequence of the 331 
disruption of the GnRH pulse generator at the level of the ARC Kiss1 neuron. However, we 332 
unexpectedly observed that in the congenital absence of NKB, the NK2R agonist significantly 333 
stimulates LH release in the absence of E2 (our present data in Tac2KO mice). These data 334 
suggest that the action of NKA is inherently stimulatory, NKB-independent and kisspeptin-335 
dependent, as NK2R agonists did not induce any LH release in Kiss1KO mice regardless of the 336 
sex steroid milieu, unlike our recent findings on the kisspeptin-independent action of NKB (19). 337 
Thus, in Tac2KO mice, where NK3R and KOR are not blocked, the activity of the ARC Kiss1 338 
neuron is significantly lower due to the absence of the stimulatory action of NKB, leading to lower 339 
basal LH levels after OVX (unpublished data and Figure 5). In this scenario, NKA is able to further 340 
stimulate Kiss1 neurons, leading to an increase in LH release. Whether this reflects 341 
heterodimerization of NK3R with NK1R, as we previously reported (9), heterodimerization with 342 
other receptors, or the convergence of intracellular pathways with NK3R’s, remains unknown. 343 
Interestingly, the congenital absence of Tac2 led to the compensatory rise of Tacr3 and a 344 
noticeable trend to increase Tacr1. This is reminiscent of the increase in Tacr2 observed in the 345 
absence of Tac1 (Tac1KO mice (11)) and could also account, at least partially, for the increase 346 
in LH by NK2R agonists in Tac2KO mice regardless of the sex steroid milieu.  347 
Altogether, these data suggest that NKA contributes to the activation of ARC Kiss1 neurons 348 
through a process that may involve auto-synaptic signaling on VMH Tac1 neurons to induce SP 349 
release (as observed by the lower induction of LH release in the presence of a NK1R-antagonist), 350 
as well as the activation of yet unknown NKA-responsive neurons that eventually further regulate 351 
ARC Kiss1 neurons (Figure 6). 352 
 353 
Overall, in this study we have demonstrated that NKA is able to advance the timing of puberty 354 
onset in females, along with SP, NKB and kisspeptin.  Moreover, it offers new insights into the 355 
interaction and mechanism of action of tachykinins in the control of LH release, especially related 356 
to NKA-NKB interaction, which remained largely unexplored. Importantly, this study suggests that 357 
in the absence of NKB, the derived hypogonadism could be compensated (and potentially 358 
reversed) by NKA, which may account for the reversal of the HH phenotype frequently observed 359 
in TAC3 deficient patients. Thus, the exogenous activation of the NKA signaling pathway may 360 
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 491 
Figure legends 492 
Figure 1. Advancement of puberty onset after chronic activation of NK2R in female mice. 493 
Repeated stimulation (every 12 h) of WT female mice with GR64349 (NK2R-A, 3 nmol/100ul/ip) 494 
or vehicle (0.9% NaCl/100ul/ip) from p23 to p32 (n≥6 per group). (A) Progression of VO, (B) mean 495 
postnatal day of VO and (C) BW the day of 50% of the control animals displayed VO. (D) Uterine 496 
weight, (E) ovarian weight and (F) serum LH levels at p32. Statistical analysis was performed 497 
using a 2-tailed t test (*p < 0.05; ***p< .001). 498 
 499 
Figure 2. Tacr2 (NK2R) is expressed in VMH Tac1 neurons. 500 
Representative double label ISH depicting co-localization of Tac1 (red) and Tacr2 (green) mRNA. 501 
(A) VMH and (C) ARC of female WT C57Bl/6 mice after 1 week of OVX. (B) VMH and (D) ARC 502 
of female WT C57Bl/6 OVX mice after 1 week of E2 replacement.  503 
 504 
Figure 3. The stimulatory action of NKA is independent of NKB in the presence of 505 
physiological circulating levels of E2. 506 
(A) LH release before (basal), 25 and 60 min after the icv injection of NK2R-Ag, senktide or the 507 
co-administration of both (600 pmol/5ul/icv) in WT OVX+E2 females (n ≥ 5 per group). *p<0.05 508 
vs. corresponding basal levels. (2 Way ANOVA followed by Tukey post hoc test). For SB222200 509 
treated mice, LH levels before (basal) SB222200 (7 nmol5ul/icv) administration and at 25 and 60 510 
minutes after injection of NK2R-Ag (600 pmol/5ul/icv), senktide (600 pmol/5ul/icv) or vehicle 511 
(0.9% NaCl/5ul/icv) in WT OVX+E2 females (n ≥ 4 per group). *p<0.05 vs. corresponding basal 512 
levels.  # p<0.05 vs. corresponding control mice at the same time point (2 Way ANOVA followed 513 
by Tukey post hoc test). (B) LH before (Basal) and at 25 and 60 minutes after injection of NK2R-514 
Ag (600 pmol/5ul/icv) in OVX+E2 WT and Tac2KO females (n≥5 per group). *p<0.05 vs. 515 
corresponding basal levels (2 Way ANOVA followed by Tukey post hoc test). 516 
 517 
Figure 4. The inhibitory action of NKA is NK3R and KOR dependent. 518 
(A) LH release before (basal), 25 and 60 min after icv injection of NK2R-Ag, senktide or the co-519 
administration of both (600 pmol/5ul/icv) in WT OVX females (n≥5 per group). *p<0.05 vs. 520 
corresponding basal levels; # p<0.05 vs. NK2R-Ag at the same time point (2 Way ANOVA 521 
followed by Tukey post hoc test). For SB222200 treated mice, LH levels before (basal) SB222200 522 
(7 nmol5ul/icv) injection and at 25 and 60 minutes after injection of NK2R-Ag (600 pmol/5ul/icv), 523 
senktide (600 pmol/5ul/icv) or vehicle (0.9% NaCl/5ul/icv) in WT OVX females (n≥5 per group). 524 
*p<0.05 vs. corresponding basal levels (2 Way ANOVA followed by Tukey post hoc test). (B) LH 525 
levels before (basal), 25 and 60 minutes after injection of naloxone (5mg/kg/100ul/ip) or vehicle 526 
(0.9% NaCl/100ul/ip) in WT OVX females (n≥5 per group). *p<0.05 vs. corresponding basal levels 527 
(2 Way ANOVA followed by Tukey post hoc test).  528 
 529 
Figure 5. The inhibitory action of NKA is NKB independent and partially SP dependent. 530 
(A) LH levels before (basal) (vehicle or NK1R-Antg (2 nmol/5ul/icv)) and at 25 and 60 minutes 531 
after injection of NK2R-Ag (600 pmol/5ul/icv) or vehicle (0.9% NaCl/5ul/icv) in OVX Tac2KO 532 
females (n≥5 per group). *p<0.05 vs. corresponding basal levels (2 Way ANOVA followed by 533 
Tukey post hoc test). (B) LH levels before (basal) (vehicle or NK1R-Antg (2 nmol/5ul/icv)) and at 534 
25 and 60 minutes after injection of NK1R-Ag (600 pmol/5ul/icv), or vehicle (0.9% NaCl/5ul/icv) 535 
in WT OVX females (n≥5 per group). *p<0.05 vs. corresponding basal levels (2 Way ANOVA 536 
followed by Tukey post hoc test); # p<0.05 vs. NK1R-Antg + vehicle injected mice levels. (C) 537 
Expression of Tac1r, Tacr2, Tacr3, Kiss1 and Pdyn in the mediobasal hypothalamus of Tac2KO 538 
females (n=9) and their WT controls (n=7). *p<0.05 Student t-test. 539 
Figure 6. Schematic representation of the proposed mechanism of action of NKA. 540 
NKA, expressed by Tac1 neurons in the VMH, regulates the activity of ARC Kiss1 neurons 541 
through two potential mechanisms: 1) through autosynaptic loops that regulate the release of SP 542 
onto Kiss1 neurons and 2) through the action of NKA on nearby (unidentified) NKA-responsive 543 
neurons that eventually contact Kiss1 neurons. 544 
